Evidence map›Paper›PMID 29504919›Full record

ArticleBMC medical genomics2018

Computational master-regulator search reveals mTOR and PI3K pathways responsible for low sensitivity of NCI-H292 and A427 lung cancer cell lines to cytotoxic action of p53 activator Nutlin-3.

Ulyana Boyarskikh, Sergey Pintus, Nikita Mandrik, Daria Stelmashenko, Ilya Kiselev, Ivan Evshin, Ruslan Sharipov, Philip Stegmaier, Fedor Kolpakov, Maxim Filipenko and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC medical genomics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Review
  2. Article
  3. Bioelectronic cell-based device provides a strategy for the treatment of the experimental model of multiple sclerosis.Journal of controlled release : official journal of the Controlled Release Society · 2022
    Article
  4. Signal pathways and precision therapy of small-cell lung cancer.Signal transduction and targeted therapy · 2022
    Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 2 countries.

Ulyana BoyarskikhInstitute of Chemical Biology and Fundamental Medicine, SBRAN, Novosibirsk, Russia.
Sergey PintusBiosoft.ru, Ltd, Novosibirsk, Russia.
Nikita MandrikBiosoft.ru, Ltd, Novosibirsk, Russia.
Daria StelmashenkoBiosoft.ru, Ltd, Novosibirsk, Russia.
Ilya KiselevBiosoft.ru, Ltd, Novosibirsk, Russia.
Ivan EvshinBiosoft.ru, Ltd, Novosibirsk, Russia.
Ruslan SharipovBiosoft.ru, Ltd, Novosibirsk, Russia.
Philip StegmaiergeneXplain GmbH, D-38302, Wolfenbüttel, Germany.
Fedor KolpakovBiosoft.ru, Ltd, Novosibirsk, Russia.
Maxim FilipenkoInstitute of Chemical Biology and Fundamental Medicine, SBRAN, Novosibirsk, Russia.
Alexander KelInstitute of Chemical Biology and Fundamental Medicine, SBRAN, Novosibirsk, Russia. alexander.kel@genexplain.com.
GeneXplain (Germany) · DEInstitute of Chemical Biology and Fundamental Medicine · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSmall molecule Nutlin-3 reactivates p53 in cancer cells by interacting with the complex between p53 and its repressor Mdm-2 and causing an increase in cancer cell apoptosis. Therefore, Nutlin-3 has potent anticancer properties. Clinical and experimental studies of Nutlin-3 showed that some cancer cells may lose sensitivity to this compound. Here we analyze possible mechanisms for insensitivity of cancer cells to Nutlin-3.

methodsWe applied upstream analysis approach implemented in geneXplain platform ( genexplain.com ) using TRANSFAC® database of transcription factors and their binding sites in genome and using TRANSPATH® database of signal transduction network with associated software such as Match™ and Composite Module Analyst (CMA).

resultsUsing genome-wide gene expression profiling we compared several lung cancer cell lines and showed that expression programs executed in Nutlin-3 insensitive cell lines significantly differ from that of Nutlin-3 sensitive cell lines. Using artificial intelligence approach embed in CMA software, we identified a set of transcription factors cooperatively binding to the promoters of genes up-regulated in the Nutlin-3 insensitive cell lines. Graph analysis of signal transduction network upstream of these transcription factors allowed us to identify potential master-regulators responsible for maintaining such low sensitivity to Nutlin-3 with the most promising candidate mTOR, which acts in the context of activated PI3K pathway. These finding were validated experimentally using an array of chemical inhibitors.

conclusionsWe showed that the Nutlin-3 insensitive cell lines are actually highly sensitive to the dual PI3K/mTOR inhibitor NVP-BEZ235, while no responding to either PI3K -specific LY294002 nor Bcl-XL specific 2,3-DCPE compounds.

Indexed as

Drug Resistance, NeoplasmApoptosisCell ProliferationHumansImidazolesLung NeoplasmsPhosphatidylinositol 3-KinasesPiperazinesProtein Kinase InhibitorsSignal TransductionTOR Serine-Threonine KinasesTumor Cells, CulturedTumor Suppressor Protein p53ImidazolesMTOR protein, humannutlin 3Phosphatidylinositol 3-KinasesPiperazinesProtein Kinase InhibitorsTOR Serine-Threonine KinasesTP53 protein, humanTumor Suppressor Protein p53Lung cancer cell linesNutlin-3p53Sensitivity to anticancer drugsTranscription factorsTRANSFAC

Identifiers

PMID29504919
PMCPMC5836833
OpenAlexW2787597215

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.